Home > > > > > Report Detail

Chronic Myelocytic Leukemia (CML) - Epidemiology Forecast to 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 50
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Chronic Myelocytic Leukemia (CML) - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Chronic Myelocytic Leukemia (CML) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Chronic Myelocytic Leukemia (CML) Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Chronic Myelocytic Leukemia (CML) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Chronic Myelocytic Leukemia (CML) outlook. It also includes the explanation of changing trends of epidemiology outlining the Chronic Myelocytic Leukemia (CML) scenario.

Chronic Myelocytic Leukemia (CML) Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Chronic Myelocytic Leukemia (CML) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

- The report covers detailed overview of Chronic Myelocytic Leukemia (CML) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

- It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

- The Chronic Myelocytic Leukemia (CML) Report assesses the disease risk and burden and highlights the unmet needs

- It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

- 10 Year Forecast

- 7MM Coverage

- Total Cases in Chronic Myelocytic Leukemia (CML)

Key assessments

- Patient Segmentation in Chronic Myelocytic Leukemia (CML)

- Chronic Myelocytic Leukemia (CML) Risk & Burden

- Factors driving growth in a specific Chronic Myelocytic Leukemia (CML) patient population

Chronic Myelocytic Leukemia (CML) - Epidemiology Forecast to 2028

Table of Contents

1. Report Introduction
2. Chronic Myelocytic Leukemia (CML) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Chronic Myelocytic Leukemia (CML) in 2016
2.2. Patient Share Distribution of Chronic Myelocytic Leukemia (CML) in 2028
3. Disease Background and Overview: Chronic Myelocytic Leukemia (CML)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Chronic Myelocytic Leukemia (CML) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Chronic Myelocytic Leukemia (CML) in 7MM - By Countries
5. Epidemiology of Chronic Myelocytic Leukemia (CML) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)
5.1.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) *
5.1.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)*
5.1.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)
5.4.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)*
5.4.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)*
5.4.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)
5.5.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)*
5.5.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)*
5.5.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)
5.6.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)*
5.6.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)*
5.6.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)
5.7.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)*
5.7.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)*
5.7.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)
5.8.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)*
5.8.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)*
5.8.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML)
5.9.3. Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML)*
5.9.4. Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML)*
5.9.5. Diagnosed Cases of the Chronic Myelocytic Leukemia (CML)
6. Unmet Needs of the Chronic Myelocytic Leukemia (CML)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM
Table 2: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028) *
Table 14: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Chronic Myelocytic Leukemia (CML) in Japan (2016-2028)

  • Global Cancer Immunomodulator Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95
    The global Cancer Immunomodulator market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ ......
  • Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 158
    According to our LPI (LP Information) latest study, the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size was valued at US$ 14070 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is forecast to a readjusted size of US$ 57240 million by 2030 with a CAGR of 22.2% during review period. The research report highlights the growth potential of the global Circulating Tumor Cells (CTCs) and Canc......
  • Global Circulating Tumor Cells Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 131
    According to our LPI (LP Information) latest study, the global Circulating Tumor Cells market size was valued at US$ 1550.1 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells is forecast to a readjusted size of US$ 5942.1 million by 2030 with a CAGR of 21.2% during review period. The research report highlights the growth potential of the global Circulating Tumor Cells market. Circulating Tumor Cells are expected to show stable growth in the future mark......
  • Global Circulating Tumor Cells Market 2024 by Company, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 125
    According to our (Global Info Research) latest study, the global Circulating Tumor Cells market size was valued at USD 1630.5 million in 2023 and is forecast to a readjusted size of USD 5681.6 million by 2030 with a CAGR of 19.5% during review period. Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of......
  • Small Molecule Targeted Cancer Therapy - Global Market Insights and Sales Trends 2024
    Published: 27-Dec-2023        Price: US 3350 Onwards        Pages: 112
    This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Small Molecule Targeted Cancer Therapy, with......
  • Global Cancer Gene Therapy Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global Cancer Gene Therapy market: According to our latest research, the global Cancer Gene Therapy market looks promising in the next 5 years. As of 2022, the global Cancer Gene Therapy market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Gene Th......
  • T-Cell Immunotherapy - Global Market Insights and Sales Trends 2024
    Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 85
    CAR T cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively. The global T-Cell Immunotherapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of T-Cell Immunotherapy in various end use industries. The expanding demands from the Stomach ......
  • Global Kaposi Sarcoma Market Status and Outlook 2023-2028
    Published: 22-Dec-2023        Price: US 3160 Onwards        Pages: 107
    Kaposi's sarcoma is a type of cancer that forms in the lining of blood and lymph vessels. The tumors (lesions) of Kaposi's sarcoma typically appear as painless purplish spots on the legs, feet or face. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking a......
  • Global Cancer Immunomodulator Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 21-Dec-2023        Price: US 3380 Onwards        Pages: 118
    Market Overview of Global Cancer Immunomodulator market: According to our latest research, the global Cancer Immunomodulator market looks promising in the next 5 years. As of 2022, the global Cancer Immunomodulator market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cance......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs